177478-27-2

Usage

Appearance

Colorless crystalline solid

Solubility

Soluble in water, slightly soluble in ethanol

Primary Use

Developing agent in black and white photographic film

Mechanism of Action

Converts exposed silver halide grains into black metallic silver

Secondary Applications

Production of hair dyes
Chemical intermediate in the synthesis of pharmaceuticals and other organic compounds

Safety Considerations

Can cause skin and eye irritation
Inhaling dust may be harmful

Upstream product

• 862271-03-2 3-(4-methoxybenzyloxy)-N-methyl-2-nitrobenzenamine 
• 177477-65-5 tert-Butyl N-(3-benzyloxy-2-nitrophenyl)-N-methylcarbamate 
• 177477-63-3 tert-butyl 3-(benzyloxy)-2-nitrophenylcarbamate 
• 94863-06-6 benzyl 3-benzyloxy-2-nitrobenzoate 
• 24115-89-7 3-benzyloxy-2-nitrobenzoic acid 
• 602-00-6 3-hydroxy-2-nitrobenzoic acid 
• 177477-68-8 3-benzyloxy-N-methyl-2-nitroaniline 

Downstream Products

• 177477-46-2 4-[2,6-dimethyl-3-[N-[4-(methylcarbamoyl)cinnamoylglycyl]-N-methylamino]benzyloxy]-2-mercapto-1-methyl-1H-benzimidazole 

Relevant academic research and scientific papers

VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS

Pyrimidine ethers and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

Benzimidazole compounds as bradykinin antagonists

PCT No. PCT/JP95/01478 Sec. 371 Date Feb. 3, 1997 Sec. 102(e) Date Feb. 3, 1997 PCT Filed Jul. 25, 1995 PCT Pub. No. WO96/04251 PCT Pub. Date Feb. 15, 1996This invention relates to a heterocyclic compound of the formula: wherein a group of the formula: is a group of the formula: etc., X is O, S or N-R5, R1 is lower alkyl, etc., R5 is hydrogen, lower alkyl, etc., R2 is hydrogen, halogen, lower alkyl, etc., R3 is halogen, lower alkyl, etc., R4 is amino optionally having suitable substituent(s), and A is lower alkylene, and a salt thereof, to processes for preparation thereof, and to a pharmaceutical composition comprising the same for the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a]pyridine moiety

Recently we reported on overcoming the species difference of our first orally active non-peptide bradykinin (BK) B2 receptor antagonists, incorporating an 8-[[3-(N-acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]- 3-halo-2-methylimidazo[1,2-α]